Results 111 to 120 of about 7,353,326 (373)
Awareness regarding female breast cancer in Kashmiri males - A study [PDF]
, 2010 Breast cancer is a major killer disease in females globally and in developing regions, where the early cancer detection facilities are unavailable, prognosis is even worse. Awareness about this disease can lead to early detection and thereby decrease the
Rather, A, Salati , SA
core +1 more source
Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer [PDF]
, 2017 Background: It is important to identify novel plasmatic biomarkers that can contribute to assessing the prognosis and outcome of breast cancer patients.
Cardelli, Patrizia +5 more
core +1 more source
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
New England Journal of Medicine, 2005 BACKGROUND Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of ...
M. Piccart-Gebhart +31 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani +14 more
wiley +1 more source
The Oncologist, 2001 Abstract Several interesting aspects of breast cancer were covered at this year's American Society of Clinical Oncology meeting. Sentinel lymph node (SN) mapping is now in widespread use, in concert with the general trend toward trying to decrease the morbidity of breast cancer surgery.
openaire +2 more sources
Celecoxib decreases prostaglandin E\u3csub\u3e2\u3c/sub\u3e concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer [PDF]
, 2006 Background Celecoxib inhibits PGE2 production in cancerous tissue. We previously reported that PGE2 levels in nipple aspirate fluid (NAF) and plasma were not decreased in women at increased breast cancer risk who received celecoxib 200 mg twice daily ...
Flynn, John T. +4 more
core +1 more source
Understanding the mechanisms of aromatase inhibitor resistance [PDF]
, 2012 Aromatase inhibitors (AIs) have a central role in the treatment of breast cancer; however, resistance is a major obstacle to optimal management. Evidence from endocrine, molecular and pathological measurements in clinical material taken before and after ...
Larionov, Alexey A, Miller, William R
core +1 more source
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
New England Journal of Medicine, 2005 BACKGROUND We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer.
E. Romond +24 more
semanticscholar +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
Journal of Cancer Research and Clinical OncologyPurpose This study aimed to evaluate the efficacy and safety of docetaxel rechallenge in HER2-negative metastatic breast cancer (MBC) patients who discontinued docetaxel for reasons other than disease progression.
Hui-Ai Zeng +7 more
doaj +1 more source